Adjuvant Sertraline Treatment for Chronic Schizophrenia : A Randomized, Double Blind, Placebo-Controlled Study

만성 정신분열증환자에 대한 Sertraline병합치료 효과

  • Lee, Min-Soo (Department of Neuropsychiatry, College of Medicine, Korea University) ;
  • Kim, Yong-Ku (Department of Neuropsychiatry, College of Medicine, Korea University) ;
  • Lee, Sang-Kyu (Department of Neuropsychiatry, College of Medicine, Korea University) ;
  • Suh, Kwang-Yoon (Department of Neuropsychiatry, College of Medicine, Korea University)
  • 이민수 (고려대학교 의과대학 신경정신과학교실) ;
  • 김용구 (고려대학교 의과대학 신경정신과학교실) ;
  • 이상규 (고려대학교 의과대학 신경정신과학교실) ;
  • 서광윤 (고려대학교 의과대학 신경정신과학교실)
  • Published : 1997.06.25

Abstract

Objective : To evaluate the clinical efficacy of adjuvant sertraline treatment in chronic schizophrenic patients, we carried out a double-blind, placebo controlled study. Method : Thirty six inpatients who fulfilled DSM-III-R criteria for chronic schizophrenia were randomly assigned to sertraline and placebo groups in a double-blinded fashion. A history of at least 2 years of illness and at least six months of hospitalization were prerequisities for inclusion in the study. Patients were received sertraline 50mg or placebo for 8 weeks in addition to their routine haloperidol regimen. Positive and Negative Syndrome Scale (PANSS), Clinical Global Impression(CGI), Simpson-Angus Scale(S-A) were evaluated at 5 points ; baseline, 2, 4, 6, and 8 weeks of treatment. Results : The groups were controlled for age, gender, and length of illness. There were no significant differences in three PANSS factros(positive, negative, general), CGI, and S-A scale scores at any between sertaline and placebo treatment. Conclusion : This placebo controlled study showed no significant effects of sertraline on negative and positive symptoms in chronic schizophrenic patients.

Keywords